Skip to content

JBIO JBIO Total Liabilities

Total Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.12B+11.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$456.46M-11.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$122.04M+62.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$31.57M+98.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$36.81M+32.2%
Vor Biopharma logo
Vor BiopharmaVOR
$657.17M+1,420%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's total liabilities?
JBIO (JBIO) reported total liabilities of $22.97M in Q1 2026.
How has JBIO's total liabilities changed year-over-year?
JBIO's total liabilities increased by 823.6% year-over-year, from $2.49M to $22.97M.
What is the long-term trend for JBIO's total liabilities?
Over 5 years (2020 to 2025), JBIO's total liabilities has grown at a 57.6% compound annual growth rate (CAGR), from $1.77M to $17.26M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.